Table 3.
Type II ANOVA modeling: Summary and associated effect sizes.
| Full model |
Age |
Fibrosis |
MAS |
||||
|---|---|---|---|---|---|---|---|
| R2 | ω2p | p values | ω2p | p values | ω2p | p values | |
| NIS2+™ | 0.42 | 0 (0, 0) | 0.4358 | 0.15 (0.1, 0.2) | <0.0001 | 0.11 (0.07, 0.15) | <0.0001 |
| FIB-4 | 0.46 | 0.34 (0.29, 0.39) | <0.0001 | 0.16 (0.11, 0.2) | <0.0001 | 0 (0, 0.01) | 0.186 |
| NFS | 0.35 | 0.27 (0.21, 0.32) | <0.0001 | 0.12 (0.08, 0.16) | <0.0001 | 0 (0, 0) | 0.8555 |
| ELF™ | 0.39 | 0.19 (0.14, 0.24) | <0.0001 | 0.17 (0.12, 0.22) | <0.0001 | 0.02 (0, 0.04) | 0.0012 |
| APRI | 0.30 | 0.01 (0, 0.02) | 0.0664 | 0.13 (0.08, 0.17) | <0.0001 | 0.05 (0.02, 0.08) | <0.0001 |
| ALT | 0.22 | 0.03 (0.01, 0.06) | <0.0001 | 0.03 (0.01, 0.06) | <0.0001 | 0.06 (0.03, 0.09) | <0.0001 |
R2 was calculated and reported as a measure of total NIT variance explained by age, fibrosis, and NAS.
ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; ELF™, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; MAS, MASLD activity score; MASLD, metabolic dysfunction-associated liver disease; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; NIT, non-invasive test.